Standardization of the Immunocytochemical Detection of Neuroblastoma Cells in Bone Marrow

Katrien Swerts ^1*, Peter F. Ambros ¹, Chantal Brouzes ¹, José M. Fernandez Navarro ¹, Nicole Gross ¹, Dyanne Rampling ¹, Roswitha Schumacher-Kuckelkorn ¹, Angela R. Sementa ¹, Ruth Ladenstein ¹ and Klaus Beiske ¹

¹ Department of Pediatric Hematology and Oncology, Ghent University Hospital, Ghent, Belgium (KS); Children's Cancer Research Institute, St. Anna Children’s Hospital, Vienna, Austria (PFA,RL); Laboratory of Hematology, Institut Gustave Roussy, Villejuif, France (CB); Unidad de Oncología Pediátrica, Hospital Infantil La Fe, Valencia, Spain (JMFN); Pediatric Oncology Research, Pediatrics, University Hospital CHUV, Lausanne, Switzerland (NG); Histopathology Department, Great Ormond Street Hospital for Children, London, United Kingdom (DR); University of Cologne, Universitätskinderklinik, Cologne, Germany (RS-K); Servizio di Anatomia Patologica, Istituto G. Gaslini, Genoa, Italy (ARS); and Department of Pathology, Rikshospitalet, Oslo, Norway (KB)

^* To whom correspondence should be addressed. E-mail: Katrien.Swerts{at}UGent.be.

Submitted on February 22, 2005
Accepted on 11 May 2005

	Abstract

Standard cytomorphological examination of bone marrow (BM) aspirates does not appear to be sensitive enough to detect single neuroblastoma cells. The SIOPEN Neuroblastoma Bone Marrow Committee developed a sensitive and reproducible anti-GD2 immunocytochemical assay and introduced morphological and immunocytological criteria for the interpretation of results. Fixed cytospins were incubated with a commercially available anti-GD2 monoclonal antibody and an APAAP kit. Cells fulfilling all morphological and immunocytological criteria were called Criteria Positive Cells (CPC’s). Not Convincingly Interpretable Cells (NCIC’s) fulfilled some but not all criteria and Negative Cells (NC’s) displayed only exclusion criteria. The genetic profile of doubtful cells was checked by FISH. Ideally, 3 x 10⁶ cells were analyzed to reach a 95% probability of detecting one tumor cell in 1 x 10⁶ mononuclear cells. Four quality control (QC) rounds were organized to validate the method. A total of 111 QC samples were analyzed. Two main improvements were achieved: in discordant cases, the range between the lowest and highest reported result was reduced by half, and discordant results were only found in samples with less than 10 CPC’s per 1 x 10⁶. This paper describes the first internationally standardized protocol to detect and quantify rare neuroblastoma cells by immunocytochemistry. This method is an indispensable tool for multicenter studies evaluating the clinical significance of minimal residual disease in neuroblastoma.

Key Words: immunocytochemistry, minimal residual disease, neuroblastoma, bone marrow

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Stutterheim, A. Gerritsen, L. Zappeij-Kannegieter, I. Kleijn, R. Dee, L. Hooft, M. M. van Noesel, M. Bierings, F. Berthold, R. Versteeg, et al. PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma J. Clin. Oncol., November 20, 2008; 26(33): 5443 - 5449. [Abstract] [Full Text] [PDF]

				N. Berois, E. Blanc, H. Ripoche, X. Mergui, F. Trajtenberg, S. Cantais, M. Barrois, P. Dessen, B. Kagedal, J. Benard, et al. ppGalNAc-T13: A New Molecular Marker of Bone Marrow Involvement in Neuroblastoma Clin. Chem., September 1, 2006; 52(9): 1701 - 1712. [Abstract] [Full Text] [PDF]

				K. Swerts, B. De Moerloose, C. Dhooge, J. Vandesompele, C. Hoyoux, K. Beiske, Y. Benoit, G. Laureys, and J. Philippe Potential Application of ELAVL4 Real-Time Quantitative Reverse Transcription-PCR for Detection of Disseminated Neuroblastoma Cells Clin. Chem., March 1, 2006; 52(3): 438 - 445. [Abstract] [Full Text] [PDF]

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact

The Journal of Histochemistry & Cytochemistry is owned, published, and licensed by The Histochemical Society © 2005